Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04618601
Other study ID # 15606
Secondary ID
Status Active, not recruiting
Phase Phase 4
First received
Last updated
Start date October 20, 2020
Est. completion date March 1, 2022

Study information

Verified date November 2020
Source Laik? General Hospital, Athens
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a prospective, single-center, open-label and randomized trial for evaluation of the effect of a 5-day administration of high doses of spironolactone (≥100mg daily) on diuresis, natriuresis, weight loss and levels of NT-proBNP in hospitalized patients with acute decompensated heart failure (ADHF). Mineralocorticoid receptor antagonists (MRAs) are recommended as standard of care (SOC) in management of heart failure (HF) patients. However, recommended doses of MRAs (up to 50mg daily) have any impact on signs and symptoms of volume overload. Therefore, the proposed study will aim to show the impact of high doses of spironolactone to improve diuresis, natriuresis, weight loss and levels of NT-proBNP in hospitalized patients with ADHF.


Description:

Congestion represents a hallmark feature of ADHF, which is present in more than 90% of patients hospitalized for this diagnosis. Intravenous loop diuretics are the mainstay of treatment. Nonetheless, nearly half of the patients who are hospitalized for AdHF continue to have residual symptoms and sign of congestion at time of discharge. Various pharmacological and non-pharmacological interventions have been proposed over the past years as potential means for relieving congestion in hospitalized ADHF patients. However, their efficacy has not been shown. Given that hyperaldosteronism is a key feature in HF, the hypothesis that administration of high doses of spironolactone can potentiate the natriuretic effects of loop diuretics and relieve congestion in the setting of ADHF has been raised. According to the most recent guidelines spironolactone can be considered in combination with loop diuretic in patients with resistant edema or insufficient symptomatic response. However, spironolactone at a dose of 100 mg daily has failed to increase diuresis in patients with ADHF. The present study will assess the effect of high per os doses of spironolactone (≥100mg) on top of SOC treatment compared with SOC treatment alone on diuresis, natriuresis, weight loss and levels of NT-proBNP in hospitalized patients with ADHF.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 50
Est. completion date March 1, 2022
Est. primary completion date December 20, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Diagnosis of acute heart failure within the past 8 hours - Two of the following: 1. edema, 2. ascites, 3. jugular vein distention, 4. pulmonary congestion - NT-proBNP >1,000 pg/ml or >3,000 pg/ml (in the presence of atrial fibrillation) - Per os mean daily loop diuretic dose equivalent to 80 mg of furosemide for at least 1 month prior to presentation and at least one of the following: 1. serum urea/serum creatinine > 50 at presentation, 2. serum creatinine increased >0.3 mg/dl compared with previous value (within the last year), 3. serum creatinine > 1.8 mg/dl. Exclusion Criteria: - pregnancy or breast feeding - current acute coronary syndrome - significant valvular disease - pulmonary embolism - allergy or intolerance to spironolactone - current mechanical circulatory support - primary hypertrophic cardiomyopathy, infiltrative cardiomyopathy - mean arterial pressure <65mmHg or systolic arterial pressure <90 mmHg at presentation - anticipated use of inotropes or vasodilators (other than renal doses of dopamine, i.e. <2.5 µg/kg/min) - anticipated need of ultrafiltration - exposure to nephrotoxic agents within 3 days of presentation - serum potassium> 5 mmol/L - per os receipt of spironolactone or eplerenone in a dose > 50 mg daily prior to presentation.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Spironolactone
Patients randomized to the high-dose spironolactone group will receive oral spironolactone (=100 mg) on top of standard of care treatment for acute heart failure immediately after randomization and in the afternoon of each subsequent day unless the serum potassium level is >5 mmol/L. The exact dose will be determined based on a pre-specified algorithm provided.

Locations

Country Name City State
Greece Laiko General Hospital Athens Attiki

Sponsors (1)

Lead Sponsor Collaborator
Laik? General Hospital, Athens

Country where clinical trial is conducted

Greece, 

References & Publications (1)

Kapelios CJ, Bonou M, Vogiatzi P, Tzanis G, Mantzouratou P, Lund LH, Barbetseas J. Association Between High-Dose Spironolactone and Decongestion in Patients with Acute Heart Failure: An Observational Retrospective Study. Am J Cardiovasc Drugs. 2018 Oct;18(5):415-422. doi: 10.1007/s40256-018-0290-3. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Daily urine output Urine output in liters per 24 hours will be tracked from enrollment to day 5. 5 days
Secondary Total urine output Urine output in total liters from enrollment to day 5 will be measured. 5 days
Secondary Total weight change Patient weight in kilos will be tracked from enrollment to day 5. 5 days
Secondary Daily weight change Patient weight in kilos will be tracked from enrollment to day 5. 5 days
Secondary Natriuresis on days 1, 3 and 5 Urine sodium will be measured on days 1, 3 and 5 5 days
Secondary Changes in natriuresis between days 1, 3 and 5 Urine sodium will be measured on days 1, 3 and 5 5 days
Secondary Changes in NT-proBNP between days 1 and 5 NT-proBNP will be measured on days 1, 3 and 5 5 days
See also
  Status Clinical Trial Phase
Completed NCT03288701 - Smart SCALEs With Bioimpedance Analysis for Treatment Guidance in Decompensated Heart Failure N/A
Enrolling by invitation NCT06036914 - A Study of Ultra High Dose Diuretics to Treat Heart Failure Phase 2
Completed NCT03387813 - Hemodynamic-GUIDEd Management of Heart Failure N/A
Completed NCT03203629 - Heart Sounds Registry
Completed NCT04281849 - Balance, Aerobic Capacity, Mobility and Strength in Patients Hospitalized for Heart Failure (BAMS-HF) Program N/A
Not yet recruiting NCT04403659 - Telemonitoring of Patients Admitted in Hospital at Home With Acute Decompensated Heart Failure - Pilot Study N/A
Completed NCT03657459 - Danger Signs in Heart Failure- Effects of Video Education N/A
Completed NCT03722069 - Dietary Sodium Intake in Acute Heart Failure N/A
Completed NCT03804827 - Sleep Disordered Breathing in Acute Congestive Heart Failure
Completed NCT06468007 - Comparative Effects of Methylprednisolone and Prednisolone on the Risk of Acute Decompensated Heart Failure - An Emulated Target Trial
Completed NCT04145635 - The Aortix CRS Pilot Study N/A
Recruiting NCT04611594 - Fluid Restriction in Patients With Heart Failure N/A
Terminated NCT04643184 - Follow-up Strategies for Fragile Patients With Decompensated Heart Failure N/A
Completed NCT03200860 - Effects of Empagliflozin on Clinical Outcomes in Patients With Acute Decompensated Heart Failure Phase 2
Terminated NCT05751772 - Improving Knowledge in Heart Failure Inpatient With Therapeutic Education N/A
Recruiting NCT03586336 - Remote Dielectric Sensing (ReDS) Assisted Diuresis in Acute Decompensated Heart Failure N/A
Recruiting NCT03103932 - Biomarker Guided Discharge of Heart Failure Patients N/A
Recruiting NCT05498584 - Targeting LOXL2 and Cardiac Fibrosis for Post-acute Heart Failure Treatment- A Prospective Study
Recruiting NCT05677100 - Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure N/A
Terminated NCT04095416 - Compression Wraps as Adjuvant Therapy in Management of Acute Systolic Heart Failure N/A